Takeda Pharmaceutical Company Limited (“Takeda”) announce on 7/10/18 that it has received unconditional clearance from the United States Federal Trade Commission (“FTC”) for the proposed acquisition of Shire plc announced on May 8, 2018 (the “Acquisition”).

The FTC’s unconditional clearance of the Acquisition is another significant milestone in the transaction process.

The Acquisition remains subject to a number of conditions, including receipt of other regulatory clearances and approval by the shareholders of both companies.